Photo credit: www.investing.com
Regeneron Pharmaceuticals Class Action Alert
NEW YORK, NY – January 26, 2025 – The Rosen Law Firm, an internationally recognized law firm focused on investor rights, is informing individuals who purchased securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023, and October 30, 2024, about a significant upcoming deadline. The deadline for lead plaintiff applications is set for March 10, 2025.
Class Action Overview
If you acquired Regeneron securities during the designated Class Period, you may be eligible for compensation at no upfront cost, thanks to a contingency fee arrangement. This allows investors to seek justice without bearing legal expenses upfront.
Next Steps for Investors
About Rosen Law Firm
The Rosen Law Firm is dedicated to representing investors worldwide with a strong emphasis on securities class actions and shareholder derivative lawsuits. The firm has a commendable history of securing significant settlements for investors, including the largest-ever securities class action settlement against a Chinese company at its time. Notably, Rosen Law Firm was recognized as the top firm by ISS Securities Class Action Services in 2017 for the greatest number of securities class action settlements and has maintained a position within the top four firms in subsequent years. In 2019 alone, the firm obtained over $438 million for its clients. Additionally, founding partner Laurence Rosen received accolades from Law360 as a prominent figure in the Plaintiffs’ Bar.
Details of the Allegations
According to the claims outlined in the lawsuit, Regeneron allegedly engaged in misleading practices throughout the Class Period. The accusations include:
- Payment of credit card fees to distributors contingent upon them not charging customers higher prices for using credit cards for Eylea, a key Regeneron product.
- These payments effectively subsidized credit card use costs for customers.
- Such practices resulted in Regeneron providing price concessions that artificially lowered the selling price of Eylea.
- This strategy was purportedly designed to give Regeneron a competitive edge, especially since retina practices are sensitive to fluctuations in medication prices.
- The company allegedly overstated Eylea’s sales by not accurately reporting credit card fee payments as price concessions.
- This oversight led to inflated Average Sales Prices (ASP) reported to federal agencies, which is a violation of the False Claims Act.
- Consequently, optimistic statements regarding Regeneron’s operations and future prospects were considered materially misleading.
The lawsuit contends that these practices caused financial harm to investors once the actual information became public.
Take Action
To join the class action regarding Regeneron, please visit Rosen Law Firm’s website. Contact options include calling Phillip Kim, Esq. at 866-767-3653 or reaching out via email at case@rosenlegal.com.
Important Note
Please be aware that no class has been certified at this stage. Until class certification occurs, investors are not represented by counsel unless they actively choose to select their own legal representation. Those who prefer not to engage at this time can remain absent class members.
To stay informed about updates and developments, follow the Rosen Law Firm on social media platforms including LinkedIn, Twitter, and Facebook.
Source
www.investing.com